Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment

Song Kwon,1,* Sung Hyun Kim,2,* Dongwoo Khang,1,3,4 Jong Yeon Lee2 1Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, South Korea; 2Department of Ophthalmology, Gil Medical Center, Gachon University, College of Medicine, Incheon 21565, South Korea; 3Department of Gachon Adv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kwon S, Kim SH, Khang D, Lee JY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	glaucoma ocular regeneration protection stem cell nanotechnology Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/28be358475fb498a999887aa09749eb1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:28be358475fb498a999887aa09749eb1
record_format	dspace
spelling	oai:doaj.org-article:28be358475fb498a999887aa09749eb12021-12-02T03:55:28ZPotential Therapeutic Usage of Nanomedicine for Glaucoma Treatment1178-2013https://doaj.org/article/28be358475fb498a999887aa09749eb12020-08-01T00:00:00Zhttps://www.dovepress.com/potential-therapeutic-usage-of-nanomedicine-for-glaucoma-treatment-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Song Kwon,1,* Sung Hyun Kim,2,* Dongwoo Khang,1,3,4 Jong Yeon Lee2 1Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, South Korea; 2Department of Ophthalmology, Gil Medical Center, Gachon University, College of Medicine, Incheon 21565, South Korea; 3Department of Gachon Advanced Institute for Health Science & Technology (GAIHST), Gachon University, Incheon 21999, South Korea; 4Department of Physiology, School of Medicine, Gachon University, Incheon 21999, South Korea*These authors contributed equally to this workCorrespondence: Jong Yeon LeeDepartment of Ophthalmology, College of Medicine, Gachon University, Incheon 21565, South KoreaEmail jongyeonlee@gilhospital.comDongwoo KhangDepartment of Physiology, School of Medicine, Gachon University, Incheon 21999, South KoreaTel/ Fax +82 32 899 1525Email dkhang@gachon.ac.krAbstract: Glaucoma is a group of diseases characterized by progressive degeneration of retinal ganglion cells, leading to irreversible blindness. Currently, intraocular pressure reduction is the only established treatment available for glaucoma. With this treatment, the progression of the disease can only be delayed and there is no recovery. In addition, the commercially available eye drops have the disadvantage of low compliance and short therapeutic time, while glaucoma surgery always has the risk of failure due to wound fibrosis. Nanotechnology can overcome the limitations of the current treatment through the encapsulation and conjugation of drugs used for lowering intraocular pressure and antifibrotic agents using biodegradable or biocompatible nanoparticles for the sustained release of the drugs to protect the damaged ocular cells. Furthermore, using nanotechnology, treatment can be administered in various forms, including eye drops, contact lens, and ocular inserts, according to the convenience of the patients. Despite the promising results of delaying the progression of glaucoma, the regeneration of damaged ocular cells, including trabecular meshwork and retinal ganglion cells, is another critical hurdle to overcome. Bone marrow-derived mesenchymal stem cells and Müller glia cells can secrete neurogenic factors that trigger the regeneration of associated cells, including trabecular meshwork and retinal ganglion cells. In conclusion, this review highlights the potential therapeutic applications of nanotechnology- and stem cell-based methods that can be employed for the protection and regeneration of ocular cells.Keywords: glaucoma, ocular regeneration, protection, stem cell, nanotechnologyKwon SKim SHKhang DLee JYDove Medical Pressarticleglaucomaocular regenerationprotectionstem cellnanotechnologyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 5745-5765 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	glaucoma ocular regeneration protection stem cell nanotechnology Medicine (General) R5-920
spellingShingle	glaucoma ocular regeneration protection stem cell nanotechnology Medicine (General) R5-920 Kwon S Kim SH Khang D Lee JY Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
description	Song Kwon,1,* Sung Hyun Kim,2,* Dongwoo Khang,1,3,4 Jong Yeon Lee2 1Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, South Korea; 2Department of Ophthalmology, Gil Medical Center, Gachon University, College of Medicine, Incheon 21565, South Korea; 3Department of Gachon Advanced Institute for Health Science & Technology (GAIHST), Gachon University, Incheon 21999, South Korea; 4Department of Physiology, School of Medicine, Gachon University, Incheon 21999, South Korea*These authors contributed equally to this workCorrespondence: Jong Yeon LeeDepartment of Ophthalmology, College of Medicine, Gachon University, Incheon 21565, South KoreaEmail jongyeonlee@gilhospital.comDongwoo KhangDepartment of Physiology, School of Medicine, Gachon University, Incheon 21999, South KoreaTel/ Fax +82 32 899 1525Email dkhang@gachon.ac.krAbstract: Glaucoma is a group of diseases characterized by progressive degeneration of retinal ganglion cells, leading to irreversible blindness. Currently, intraocular pressure reduction is the only established treatment available for glaucoma. With this treatment, the progression of the disease can only be delayed and there is no recovery. In addition, the commercially available eye drops have the disadvantage of low compliance and short therapeutic time, while glaucoma surgery always has the risk of failure due to wound fibrosis. Nanotechnology can overcome the limitations of the current treatment through the encapsulation and conjugation of drugs used for lowering intraocular pressure and antifibrotic agents using biodegradable or biocompatible nanoparticles for the sustained release of the drugs to protect the damaged ocular cells. Furthermore, using nanotechnology, treatment can be administered in various forms, including eye drops, contact lens, and ocular inserts, according to the convenience of the patients. Despite the promising results of delaying the progression of glaucoma, the regeneration of damaged ocular cells, including trabecular meshwork and retinal ganglion cells, is another critical hurdle to overcome. Bone marrow-derived mesenchymal stem cells and Müller glia cells can secrete neurogenic factors that trigger the regeneration of associated cells, including trabecular meshwork and retinal ganglion cells. In conclusion, this review highlights the potential therapeutic applications of nanotechnology- and stem cell-based methods that can be employed for the protection and regeneration of ocular cells.Keywords: glaucoma, ocular regeneration, protection, stem cell, nanotechnology
format	article
author	Kwon S Kim SH Khang D Lee JY
author_facet	Kwon S Kim SH Khang D Lee JY
author_sort	Kwon S
title	Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
title_short	Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
title_full	Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
title_fullStr	Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
title_full_unstemmed	Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
title_sort	potential therapeutic usage of nanomedicine for glaucoma treatment
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/28be358475fb498a999887aa09749eb1
work_keys_str_mv	AT kwons potentialtherapeuticusageofnanomedicineforglaucomatreatment AT kimsh potentialtherapeuticusageofnanomedicineforglaucomatreatment AT khangd potentialtherapeuticusageofnanomedicineforglaucomatreatment AT leejy potentialtherapeuticusageofnanomedicineforglaucomatreatment
_version_	1718401536973864960

Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment

Ejemplares similares